Evidence map›Paper›PMID 20189880›Full record

ArticleThe Lancet. Neurology2010

Testing the amyloid hypothesis of Alzheimer's disease in vivo.

Sam Gandy

Abstract readLetterComment
In one paragraph

Article in The Lancet. Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Sam Gandy

Funding

STUDIES OF CHOLINERGIC SYSTEMS AND AMYLOIDOGENESISP01AG010491 · NIA · THOMAS JEFFERSON UNIVERSITY · PI GANDY, SAMUEL E. · 1991 to 2009
$11.1M
Model for SorCS1-mediated Diabetes with DementiaR01NS075685 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GANDY, SAMUEL E. · 2012 to 2015
$1.5M
NIA NIH HHS P01 AG010491NINDS NIH HHS R01 NS075685
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Models, NeurologicalAlzheimer DiseaseAmyloidAniline CompoundsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersBrainGenetic Predisposition to DiseaseHumansImmunization, PassiveImmunologic FactorsPositron-Emission TomographyThiazolesTreatment Outcome2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloidAniline CompoundsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedbapineuzumabBiomarkersImmunologic FactorsThiazoles

Identifiers

PMID20189880
PMCPMC3274723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.